Novo Nordisk在试验后为肥胖药物CagriSema辩护, Novo Nordisk defends its obesity drug CagriSema after trial shows lower weight loss than expected.

丹麦Novo Nordisk制药公司为肥胖药物CagriSema辩护, 实验结果显示, 患者体重损失了15.7%, 低于初步预测。 Danish pharmaceutical company Novo Nordisk is defending its obesity drug, CagriSema, after trial results showed patients lost 15.7% of their weight, below initial forecasts. 首席执行官 Lars Fruergaard Jørgensen 坚称，尽管对其试验沟通提出了批评，但该药物仍然是一种重要的治疗方法。 CEO Lars Fruergaard Jørgensen insists the drug remains a significant treatment despite criticism over its trial communication. Novo Nordisk目前正在进行新的试验,即Resefine 11,以进一步评估药物的潜力。 Novo Nordisk is now conducting a new trial, REDEFINE 11, to further assess the drug's potential.